

Global Myelodysplastic Syndrome (MDS) Treatment Market Growth 2023-2029

<https://marketpublishers.com/r/G8D384EC1135EN.html>

Date: February 2023

Pages: 96

Price: US\$ 3,660.00 (Single User License)

ID: G8D384EC1135EN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

Myelodysplastic (MDS) syndrome is a type of bone marrow disorder, where bone marrow is unable to produce healthy and mature blood cells. The immature blood cells called as blasts, get stored in the bone marrow and blood and obstruct the natural function of the hematological system which results in depletion of healthy red blood cells, platelets, and white blood cells. Myelodysplastic syndrome is usually seen in geriatric population and more often in older men than women. This syndrome is characterized by certain chromosomal mutations in Janus Kinase gene which include deletion of q arm in one or more chromosomes and complete deletion of chromosome 5 or 7 and an extra copy of chromosome 8.

LPI (LP Information)' newest research report, the "Myelodysplastic Syndrome (MDS) Treatment Industry Forecast" looks at past sales and reviews total world Myelodysplastic Syndrome (MDS) Treatment sales in 2022, providing a comprehensive analysis by region and market sector of projected Myelodysplastic Syndrome (MDS) Treatment sales for 2023 through 2029. With Myelodysplastic Syndrome (MDS) Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Myelodysplastic Syndrome (MDS) Treatment industry.

This Insight Report provides a comprehensive analysis of the global Myelodysplastic Syndrome (MDS) Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Myelodysplastic Syndrome (MDS) Treatment portfolios and capabilities,

market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Myelodysplastic Syndrome (MDS) Treatment market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Myelodysplastic Syndrome (MDS) Treatment and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Myelodysplastic Syndrome (MDS) Treatment.

The global Myelodysplastic Syndrome (MDS) Treatment market size is projected to grow from US\$ million in 2022 to US\$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

According to the American Cancer Society, the incidence rate for myelodysplastic syndrome is 13,000 new cases each year which happens at a rate of 4.8 cases per 100,000 people. This trend is heavily affected or rather influenced by the average age of the population which, according to the World Health Organization (WHO), is increasing and is expected to double from 12% to 22% between 2015 and 2050.

This report presents a comprehensive overview, market shares, and growth opportunities of Myelodysplastic Syndrome (MDS) Treatment market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type

Azacitidine

Lenalidomide

Decitabine

Deferasirox

Segmentation by application

Refractory Cytopenia with Unilineage Dysplasia

Refractory Anemia with Ringed Sideroblasts

Others

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Novartis AG

Celgene Corporation

Otsuka Pharmaceutical Co., Ltd

Sandoz Inc

Dr Reddys Laboratories Limited

Pharmascience Inc

Accord Healthcare Ltd

Mylan N.V.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Myelodysplastic Syndrome (MDS) Treatment market?

What factors are driving Myelodysplastic Syndrome (MDS) Treatment market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Myelodysplastic Syndrome (MDS) Treatment market opportunities vary by end market size?

How does Myelodysplastic Syndrome (MDS) Treatment break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview

- 2.1.1 Global Myelodysplastic Syndrome (MDS) Treatment Annual Sales 2018-2029

- 2.1.2 World Current & Future Analysis for Myelodysplastic Syndrome (MDS)

Treatment by Geographic Region, 2018, 2022 & 2029

- 2.1.3 World Current & Future Analysis for Myelodysplastic Syndrome (MDS)

Treatment by Country/Region, 2018, 2022 & 2029

2.2 Myelodysplastic Syndrome (MDS) Treatment Segment by Type

- 2.2.1 Azacitidine

- 2.2.2 Lenalidomide

- 2.2.3 Decitabine

- 2.2.4 Deferasirox

2.3 Myelodysplastic Syndrome (MDS) Treatment Sales by Type

- 2.3.1 Global Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Type (2018-2023)

- 2.3.2 Global Myelodysplastic Syndrome (MDS) Treatment Revenue and Market Share by Type (2018-2023)

- 2.3.3 Global Myelodysplastic Syndrome (MDS) Treatment Sale Price by Type (2018-2023)

2.4 Myelodysplastic Syndrome (MDS) Treatment Segment by Application

- 2.4.1 Refractory Cytopenia with Unilineage Dysplasia

- 2.4.2 Refractory Anemia with Ringed Sideroblasts

- 2.4.3 Others

2.5 Myelodysplastic Syndrome (MDS) Treatment Sales by Application

- 2.5.1 Global Myelodysplastic Syndrome (MDS) Treatment Sale Market Share by

Application (2018-2023)

2.5.2 Global Myelodysplastic Syndrome (MDS) Treatment Revenue and Market Share by Application (2018-2023)

2.5.3 Global Myelodysplastic Syndrome (MDS) Treatment Sale Price by Application (2018-2023)

3 GLOBAL MYELOYDYSPLASTIC SYNDROME (MDS) TREATMENT BY COMPANY

3.1 Global Myelodysplastic Syndrome (MDS) Treatment Breakdown Data by Company

3.1.1 Global Myelodysplastic Syndrome (MDS) Treatment Annual Sales by Company (2018-2023)

3.1.2 Global Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Company (2018-2023)

3.2 Global Myelodysplastic Syndrome (MDS) Treatment Annual Revenue by Company (2018-2023)

3.2.1 Global Myelodysplastic Syndrome (MDS) Treatment Revenue by Company (2018-2023)

3.2.2 Global Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Company (2018-2023)

3.3 Global Myelodysplastic Syndrome (MDS) Treatment Sale Price by Company

3.4 Key Manufacturers Myelodysplastic Syndrome (MDS) Treatment Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Myelodysplastic Syndrome (MDS) Treatment Product Location Distribution

3.4.2 Players Myelodysplastic Syndrome (MDS) Treatment Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

4 WORLD HISTORIC REVIEW FOR MYELOYDYSPLASTIC SYNDROME (MDS) TREATMENT BY GEOGRAPHIC REGION

4.1 World Historic Myelodysplastic Syndrome (MDS) Treatment Market Size by Geographic Region (2018-2023)

4.1.1 Global Myelodysplastic Syndrome (MDS) Treatment Annual Sales by Geographic Region (2018-2023)

4.1.2 Global Myelodysplastic Syndrome (MDS) Treatment Annual Revenue by

Geographic Region (2018-2023)

4.2 World Historic Myelodysplastic Syndrome (MDS) Treatment Market Size by Country/Region (2018-2023)

4.2.1 Global Myelodysplastic Syndrome (MDS) Treatment Annual Sales by Country/Region (2018-2023)

4.2.2 Global Myelodysplastic Syndrome (MDS) Treatment Annual Revenue by Country/Region (2018-2023)

4.3 Americas Myelodysplastic Syndrome (MDS) Treatment Sales Growth

4.4 APAC Myelodysplastic Syndrome (MDS) Treatment Sales Growth

4.5 Europe Myelodysplastic Syndrome (MDS) Treatment Sales Growth

4.6 Middle East & Africa Myelodysplastic Syndrome (MDS) Treatment Sales Growth

5 AMERICAS

5.1 Americas Myelodysplastic Syndrome (MDS) Treatment Sales by Country

5.1.1 Americas Myelodysplastic Syndrome (MDS) Treatment Sales by Country (2018-2023)

5.1.2 Americas Myelodysplastic Syndrome (MDS) Treatment Revenue by Country (2018-2023)

5.2 Americas Myelodysplastic Syndrome (MDS) Treatment Sales by Type

5.3 Americas Myelodysplastic Syndrome (MDS) Treatment Sales by Application

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Myelodysplastic Syndrome (MDS) Treatment Sales by Region

6.1.1 APAC Myelodysplastic Syndrome (MDS) Treatment Sales by Region (2018-2023)

6.1.2 APAC Myelodysplastic Syndrome (MDS) Treatment Revenue by Region (2018-2023)

6.2 APAC Myelodysplastic Syndrome (MDS) Treatment Sales by Type

6.3 APAC Myelodysplastic Syndrome (MDS) Treatment Sales by Application

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

- 6.8 India
- 6.9 Australia
- 6.10 China Taiwan

7 EUROPE

- 7.1 Europe Myelodysplastic Syndrome (MDS) Treatment by Country
 - 7.1.1 Europe Myelodysplastic Syndrome (MDS) Treatment Sales by Country (2018-2023)
 - 7.1.2 Europe Myelodysplastic Syndrome (MDS) Treatment Revenue by Country (2018-2023)
- 7.2 Europe Myelodysplastic Syndrome (MDS) Treatment Sales by Type
- 7.3 Europe Myelodysplastic Syndrome (MDS) Treatment Sales by Application
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia

8 MIDDLE EAST & AFRICA

- 8.1 Middle East & Africa Myelodysplastic Syndrome (MDS) Treatment by Country
 - 8.1.1 Middle East & Africa Myelodysplastic Syndrome (MDS) Treatment Sales by Country (2018-2023)
 - 8.1.2 Middle East & Africa Myelodysplastic Syndrome (MDS) Treatment Revenue by Country (2018-2023)
- 8.2 Middle East & Africa Myelodysplastic Syndrome (MDS) Treatment Sales by Type
- 8.3 Middle East & Africa Myelodysplastic Syndrome (MDS) Treatment Sales by Application
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Myelodysplastic Syndrome (MDS) Treatment

10.3 Manufacturing Process Analysis of Myelodysplastic Syndrome (MDS) Treatment

10.4 Industry Chain Structure of Myelodysplastic Syndrome (MDS) Treatment

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Myelodysplastic Syndrome (MDS) Treatment Distributors

11.3 Myelodysplastic Syndrome (MDS) Treatment Customer

12 WORLD FORECAST REVIEW FOR MYELOYDYSPLASTIC SYNDROME (MDS) TREATMENT BY GEOGRAPHIC REGION

12.1 Global Myelodysplastic Syndrome (MDS) Treatment Market Size Forecast by Region

12.1.1 Global Myelodysplastic Syndrome (MDS) Treatment Forecast by Region (2024-2029)

12.1.2 Global Myelodysplastic Syndrome (MDS) Treatment Annual Revenue Forecast by Region (2024-2029)

12.2 Americas Forecast by Country

12.3 APAC Forecast by Region

12.4 Europe Forecast by Country

12.5 Middle East & Africa Forecast by Country

12.6 Global Myelodysplastic Syndrome (MDS) Treatment Forecast by Type

12.7 Global Myelodysplastic Syndrome (MDS) Treatment Forecast by Application

13 KEY PLAYERS ANALYSIS

13.1 Novartis AG

13.1.1 Novartis AG Company Information

13.1.2 Novartis AG Myelodysplastic Syndrome (MDS) Treatment Product Portfolios

and Specifications

13.1.3 Novartis AG Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)

13.1.4 Novartis AG Main Business Overview

13.1.5 Novartis AG Latest Developments

13.2 Celgene Corporation

13.2.1 Celgene Corporation Company Information

13.2.2 Celgene Corporation Myelodysplastic Syndrome (MDS) Treatment Product Portfolios and Specifications

13.2.3 Celgene Corporation Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)

13.2.4 Celgene Corporation Main Business Overview

13.2.5 Celgene Corporation Latest Developments

13.3 Otsuka Pharmaceutical Co., Ltd

13.3.1 Otsuka Pharmaceutical Co., Ltd Company Information

13.3.2 Otsuka Pharmaceutical Co., Ltd Myelodysplastic Syndrome (MDS) Treatment Product Portfolios and Specifications

13.3.3 Otsuka Pharmaceutical Co., Ltd Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)

13.3.4 Otsuka Pharmaceutical Co., Ltd Main Business Overview

13.3.5 Otsuka Pharmaceutical Co., Ltd Latest Developments

13.4 Sandoz Inc

13.4.1 Sandoz Inc Company Information

13.4.2 Sandoz Inc Myelodysplastic Syndrome (MDS) Treatment Product Portfolios and Specifications

13.4.3 Sandoz Inc Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)

13.4.4 Sandoz Inc Main Business Overview

13.4.5 Sandoz Inc Latest Developments

13.5 Dr Reddys Laboratories Limited

13.5.1 Dr Reddys Laboratories Limited Company Information

13.5.2 Dr Reddys Laboratories Limited Myelodysplastic Syndrome (MDS) Treatment Product Portfolios and Specifications

13.5.3 Dr Reddys Laboratories Limited Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)

13.5.4 Dr Reddys Laboratories Limited Main Business Overview

13.5.5 Dr Reddys Laboratories Limited Latest Developments

13.6 Pharmascience Inc

13.6.1 Pharmascience Inc Company Information

13.6.2 Pharmascience Inc Myelodysplastic Syndrome (MDS) Treatment Product Portfolios and Specifications

13.6.3 Pharmascience Inc Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)

13.6.4 Pharmascience Inc Main Business Overview

13.6.5 Pharmascience Inc Latest Developments

13.7 Accord Healthcare Ltd

13.7.1 Accord Healthcare Ltd Company Information

13.7.2 Accord Healthcare Ltd Myelodysplastic Syndrome (MDS) Treatment Product Portfolios and Specifications

13.7.3 Accord Healthcare Ltd Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)

13.7.4 Accord Healthcare Ltd Main Business Overview

13.7.5 Accord Healthcare Ltd Latest Developments

13.8 Mylan N.V.

13.8.1 Mylan N.V. Company Information

13.8.2 Mylan N.V. Myelodysplastic Syndrome (MDS) Treatment Product Portfolios and Specifications

13.8.3 Mylan N.V. Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)

13.8.4 Mylan N.V. Main Business Overview

13.8.5 Mylan N.V. Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

- Table 1. Myelodysplastic Syndrome (MDS) Treatment Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & (\$ millions)
- Table 2. Myelodysplastic Syndrome (MDS) Treatment Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & (\$ millions)
- Table 3. Major Players of Azacitidine
- Table 4. Major Players of Lenalidomide
- Table 5. Major Players of Decitabine
- Table 6. Major Players of Deferasirox
- Table 7. Global Myelodysplastic Syndrome (MDS) Treatment Sales by Type (2018-2023) & (K Units)
- Table 8. Global Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Type (2018-2023)
- Table 9. Global Myelodysplastic Syndrome (MDS) Treatment Revenue by Type (2018-2023) & (\$ million)
- Table 10. Global Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Type (2018-2023)
- Table 11. Global Myelodysplastic Syndrome (MDS) Treatment Sale Price by Type (2018-2023) & (USD/Unit)
- Table 12. Global Myelodysplastic Syndrome (MDS) Treatment Sales by Application (2018-2023) & (K Units)
- Table 13. Global Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Application (2018-2023)
- Table 14. Global Myelodysplastic Syndrome (MDS) Treatment Revenue by Application (2018-2023)
- Table 15. Global Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Application (2018-2023)
- Table 16. Global Myelodysplastic Syndrome (MDS) Treatment Sale Price by Application (2018-2023) & (USD/Unit)
- Table 17. Global Myelodysplastic Syndrome (MDS) Treatment Sales by Company (2018-2023) & (K Units)
- Table 18. Global Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Company (2018-2023)
- Table 19. Global Myelodysplastic Syndrome (MDS) Treatment Revenue by Company (2018-2023) (\$ Millions)
- Table 20. Global Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share

by Company (2018-2023)

Table 21. Global Myelodysplastic Syndrome (MDS) Treatment Sale Price by Company (2018-2023) & (USD/Unit)

Table 22. Key Manufacturers Myelodysplastic Syndrome (MDS) Treatment Producing Area Distribution and Sales Area

Table 23. Players Myelodysplastic Syndrome (MDS) Treatment Products Offered

Table 24. Myelodysplastic Syndrome (MDS) Treatment Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)

Table 25. New Products and Potential Entrants

Table 26. Mergers & Acquisitions, Expansion

Table 27. Global Myelodysplastic Syndrome (MDS) Treatment Sales by Geographic Region (2018-2023) & (K Units)

Table 28. Global Myelodysplastic Syndrome (MDS) Treatment Sales Market Share Geographic Region (2018-2023)

Table 29. Global Myelodysplastic Syndrome (MDS) Treatment Revenue by Geographic Region (2018-2023) & (\$ millions)

Table 30. Global Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Geographic Region (2018-2023)

Table 31. Global Myelodysplastic Syndrome (MDS) Treatment Sales by Country/Region (2018-2023) & (K Units)

Table 32. Global Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Country/Region (2018-2023)

Table 33. Global Myelodysplastic Syndrome (MDS) Treatment Revenue by Country/Region (2018-2023) & (\$ millions)

Table 34. Global Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Country/Region (2018-2023)

Table 35. Americas Myelodysplastic Syndrome (MDS) Treatment Sales by Country (2018-2023) & (K Units)

Table 36. Americas Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Country (2018-2023)

Table 37. Americas Myelodysplastic Syndrome (MDS) Treatment Revenue by Country (2018-2023) & (\$ Millions)

Table 38. Americas Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Country (2018-2023)

Table 39. Americas Myelodysplastic Syndrome (MDS) Treatment Sales by Type (2018-2023) & (K Units)

Table 40. Americas Myelodysplastic Syndrome (MDS) Treatment Sales by Application (2018-2023) & (K Units)

Table 41. APAC Myelodysplastic Syndrome (MDS) Treatment Sales by Region

(2018-2023) & (K Units)

Table 42. APAC Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Region (2018-2023)

Table 43. APAC Myelodysplastic Syndrome (MDS) Treatment Revenue by Region (2018-2023) & (\$ Millions)

Table 44. APAC Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Region (2018-2023)

Table 45. APAC Myelodysplastic Syndrome (MDS) Treatment Sales by Type (2018-2023) & (K Units)

Table 46. APAC Myelodysplastic Syndrome (MDS) Treatment Sales by Application (2018-2023) & (K Units)

Table 47. Europe Myelodysplastic Syndrome (MDS) Treatment Sales by Country (2018-2023) & (K Units)

Table 48. Europe Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Country (2018-2023)

Table 49. Europe Myelodysplastic Syndrome (MDS) Treatment Revenue by Country (2018-2023) & (\$ Millions)

Table 50. Europe Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Country (2018-2023)

Table 51. Europe Myelodysplastic Syndrome (MDS) Treatment Sales by Type (2018-2023) & (K Units)

Table 52. Europe Myelodysplastic Syndrome (MDS) Treatment Sales by Application (2018-2023) & (K Units)

Table 53. Middle East & Africa Myelodysplastic Syndrome (MDS) Treatment Sales by Country (2018-2023) & (K Units)

Table 54. Middle East & Africa Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Country (2018-2023)

Table 55. Middle East & Africa Myelodysplastic Syndrome (MDS) Treatment Revenue by Country (2018-2023) & (\$ Millions)

Table 56. Middle East & Africa Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Country (2018-2023)

Table 57. Middle East & Africa Myelodysplastic Syndrome (MDS) Treatment Sales by Type (2018-2023) & (K Units)

Table 58. Middle East & Africa Myelodysplastic Syndrome (MDS) Treatment Sales by Application (2018-2023) & (K Units)

Table 59. Key Market Drivers & Growth Opportunities of Myelodysplastic Syndrome (MDS) Treatment

Table 60. Key Market Challenges & Risks of Myelodysplastic Syndrome (MDS) Treatment

Table 61. Key Industry Trends of Myelodysplastic Syndrome (MDS) Treatment
Table 62. Myelodysplastic Syndrome (MDS) Treatment Raw Material
Table 63. Key Suppliers of Raw Materials
Table 64. Myelodysplastic Syndrome (MDS) Treatment Distributors List
Table 65. Myelodysplastic Syndrome (MDS) Treatment Customer List
Table 66. Global Myelodysplastic Syndrome (MDS) Treatment Sales Forecast by Region (2024-2029) & (K Units)
Table 67. Global Myelodysplastic Syndrome (MDS) Treatment Revenue Forecast by Region (2024-2029) & (\$ millions)
Table 68. Americas Myelodysplastic Syndrome (MDS) Treatment Sales Forecast by Country (2024-2029) & (K Units)
Table 69. Americas Myelodysplastic Syndrome (MDS) Treatment Revenue Forecast by Country (2024-2029) & (\$ millions)
Table 70. APAC Myelodysplastic Syndrome (MDS) Treatment Sales Forecast by Region (2024-2029) & (K Units)
Table 71. APAC Myelodysplastic Syndrome (MDS) Treatment Revenue Forecast by Region (2024-2029) & (\$ millions)
Table 72. Europe Myelodysplastic Syndrome (MDS) Treatment Sales Forecast by Country (2024-2029) & (K Units)
Table 73. Europe Myelodysplastic Syndrome (MDS) Treatment Revenue Forecast by Country (2024-2029) & (\$ millions)
Table 74. Middle East & Africa Myelodysplastic Syndrome (MDS) Treatment Sales Forecast by Country (2024-2029) & (K Units)
Table 75. Middle East & Africa Myelodysplastic Syndrome (MDS) Treatment Revenue Forecast by Country (2024-2029) & (\$ millions)
Table 76. Global Myelodysplastic Syndrome (MDS) Treatment Sales Forecast by Type (2024-2029) & (K Units)
Table 77. Global Myelodysplastic Syndrome (MDS) Treatment Revenue Forecast by Type (2024-2029) & (\$ Millions)
Table 78. Global Myelodysplastic Syndrome (MDS) Treatment Sales Forecast by Application (2024-2029) & (K Units)
Table 79. Global Myelodysplastic Syndrome (MDS) Treatment Revenue Forecast by Application (2024-2029) & (\$ Millions)
Table 80. Novartis AG Basic Information, Myelodysplastic Syndrome (MDS) Treatment Manufacturing Base, Sales Area and Its Competitors
Table 81. Novartis AG Myelodysplastic Syndrome (MDS) Treatment Product Portfolios and Specifications
Table 82. Novartis AG Myelodysplastic Syndrome (MDS) Treatment Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2018-2023)

Table 83. Novartis AG Main Business

Table 84. Novartis AG Latest Developments

Table 85. Celgene Corporation Basic Information, Myelodysplastic Syndrome (MDS) Treatment Manufacturing Base, Sales Area and Its Competitors

Table 86. Celgene Corporation Myelodysplastic Syndrome (MDS) Treatment Product Portfolios and Specifications

Table 87. Celgene Corporation Myelodysplastic Syndrome (MDS) Treatment Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2018-2023)

Table 88. Celgene Corporation Main Business

Table 89. Celgene Corporation Latest Developments

Table 90. Otsuka Pharmaceutical Co., Ltd Basic Information, Myelodysplastic Syndrome (MDS) Treatment Manufacturing Base, Sales Area and Its Competitors

Table 91. Otsuka Pharmaceutical Co., Ltd Myelodysplastic Syndrome (MDS) Treatment Product Portfolios and Specifications

Table 92. Otsuka Pharmaceutical Co., Ltd Myelodysplastic Syndrome (MDS) Treatment Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2018-2023)

Table 93. Otsuka Pharmaceutical Co., Ltd Main Business

Table 94. Otsuka Pharmaceutical Co., Ltd Latest Developments

Table 95. Sandoz Inc Basic Information, Myelodysplastic Syndrome (MDS) Treatment Manufacturing Base, Sales Area and Its Competitors

Table 96. Sandoz Inc Myelodysplastic Syndrome (MDS) Treatment Product Portfolios and Specifications

Table 97. Sandoz Inc Myelodysplastic Syndrome (MDS) Treatment Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2018-2023)

Table 98. Sandoz Inc Main Business

Table 99. Sandoz Inc Latest Developments

Table 100. Dr Reddys Laboratories Limited Basic Information, Myelodysplastic Syndrome (MDS) Treatment Manufacturing Base, Sales Area and Its Competitors

Table 101. Dr Reddys Laboratories Limited Myelodysplastic Syndrome (MDS) Treatment Product Portfolios and Specifications

Table 102. Dr Reddys Laboratories Limited Myelodysplastic Syndrome (MDS) Treatment Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2018-2023)

Table 103. Dr Reddys Laboratories Limited Main Business

Table 104. Dr Reddys Laboratories Limited Latest Developments

Table 105. Pharmascience Inc Basic Information, Myelodysplastic Syndrome (MDS) Treatment Manufacturing Base, Sales Area and Its Competitors

Table 106. Pharmascience Inc Myelodysplastic Syndrome (MDS) Treatment Product Portfolios and Specifications

Table 107. Pharmascience Inc Myelodysplastic Syndrome (MDS) Treatment Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2018-2023)

Table 108. Pharmascience Inc Main Business

Table 109. Pharmascience Inc Latest Developments

Table 110. Accord Healthcare Ltd Basic Information, Myelodysplastic Syndrome (MDS) Treatment Manufacturing Base, Sales Area and Its Competitors

Table 111. Accord Healthcare Ltd Myelodysplastic Syndrome (MDS) Treatment Product Portfolios and Specifications

Table 112. Accord Healthcare Ltd Myelodysplastic Syndrome (MDS) Treatment Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2018-2023)

Table 113. Accord Healthcare Ltd Main Business

Table 114. Accord Healthcare Ltd Latest Developments

Table 115. Mylan N.V. Basic Information, Myelodysplastic Syndrome (MDS) Treatment Manufacturing Base, Sales Area and Its Competitors

Table 116. Mylan N.V. Myelodysplastic Syndrome (MDS) Treatment Product Portfolios and Specifications

Table 117. Mylan N.V. Myelodysplastic Syndrome (MDS) Treatment Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2018-2023)

Table 118. Mylan N.V. Main Business

Table 119. Mylan N.V. Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Myelodysplastic Syndrome (MDS) Treatment
- Figure 2. Myelodysplastic Syndrome (MDS) Treatment Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Myelodysplastic Syndrome (MDS) Treatment Sales Growth Rate 2018-2029 (K Units)
- Figure 7. Global Myelodysplastic Syndrome (MDS) Treatment Revenue Growth Rate 2018-2029 (\$ Millions)
- Figure 8. Myelodysplastic Syndrome (MDS) Treatment Sales by Region (2018, 2022 & 2029) & (\$ Millions)
- Figure 9. Product Picture of Azacitidine
- Figure 10. Product Picture of Lenalidomide
- Figure 11. Product Picture of Decitabine
- Figure 12. Product Picture of Deferasirox
- Figure 13. Global Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Type in 2022
- Figure 14. Global Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Type (2018-2023)
- Figure 15. Myelodysplastic Syndrome (MDS) Treatment Consumed in Refractory Cytopenia with Unilineage Dysplasia
- Figure 16. Global Myelodysplastic Syndrome (MDS) Treatment Market: Refractory Cytopenia with Unilineage Dysplasia (2018-2023) & (K Units)
- Figure 17. Myelodysplastic Syndrome (MDS) Treatment Consumed in Refractory Anemia with Ringed Sideroblasts
- Figure 18. Global Myelodysplastic Syndrome (MDS) Treatment Market: Refractory Anemia with Ringed Sideroblasts (2018-2023) & (K Units)
- Figure 19. Myelodysplastic Syndrome (MDS) Treatment Consumed in Others
- Figure 20. Global Myelodysplastic Syndrome (MDS) Treatment Market: Others (2018-2023) & (K Units)
- Figure 21. Global Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Application (2022)
- Figure 22. Global Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Application in 2022
- Figure 23. Myelodysplastic Syndrome (MDS) Treatment Sales Market by Company in

2022 (K Units)

Figure 24. Global Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Company in 2022

Figure 25. Myelodysplastic Syndrome (MDS) Treatment Revenue Market by Company in 2022 (\$ Million)

Figure 26. Global Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Company in 2022

Figure 27. Global Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Geographic Region (2018-2023)

Figure 28. Global Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Geographic Region in 2022

Figure 29. Americas Myelodysplastic Syndrome (MDS) Treatment Sales 2018-2023 (K Units)

Figure 30. Americas Myelodysplastic Syndrome (MDS) Treatment Revenue 2018-2023 (\$ Millions)

Figure 31. APAC Myelodysplastic Syndrome (MDS) Treatment Sales 2018-2023 (K Units)

Figure 32. APAC Myelodysplastic Syndrome (MDS) Treatment Revenue 2018-2023 (\$ Millions)

Figure 33. Europe Myelodysplastic Syndrome (MDS) Treatment Sales 2018-2023 (K Units)

Figure 34. Europe Myelodysplastic Syndrome (MDS) Treatment Revenue 2018-2023 (\$ Millions)

Figure 35. Middle East & Africa Myelodysplastic Syndrome (MDS) Treatment Sales 2018-2023 (K Units)

Figure 36. Middle East & Africa Myelodysplastic Syndrome (MDS) Treatment Revenue 2018-2023 (\$ Millions)

Figure 37. Americas Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Country in 2022

Figure 38. Americas Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Country in 2022

Figure 39. Americas Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Type (2018-2023)

Figure 40. Americas Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Application (2018-2023)

Figure 41. United States Myelodysplastic Syndrome (MDS) Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 42. Canada Myelodysplastic Syndrome (MDS) Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 43. Mexico Myelodysplastic Syndrome (MDS) Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 44. Brazil Myelodysplastic Syndrome (MDS) Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 45. APAC Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Region in 2022

Figure 46. APAC Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Regions in 2022

Figure 47. APAC Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Type (2018-2023)

Figure 48. APAC Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Application (2018-2023)

Figure 49. China Myelodysplastic Syndrome (MDS) Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 50. Japan Myelodysplastic Syndrome (MDS) Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 51. South Korea Myelodysplastic Syndrome (MDS) Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 52. Southeast Asia Myelodysplastic Syndrome (MDS) Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 53. India Myelodysplastic Syndrome (MDS) Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 54. Australia Myelodysplastic Syndrome (MDS) Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 55. China Taiwan Myelodysplastic Syndrome (MDS) Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 56. Europe Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Country in 2022

Figure 57. Europe Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Country in 2022

Figure 58. Europe Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Type (2018-2023)

Figure 59. Europe Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Application (2018-2023)

Figure 60. Germany Myelodysplastic Syndrome (MDS) Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 61. France Myelodysplastic Syndrome (MDS) Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 62. UK Myelodysplastic Syndrome (MDS) Treatment Revenue Growth

2018-2023 (\$ Millions)

Figure 63. Italy Myelodysplastic Syndrome (MDS) Treatment Revenue Growth

2018-2023 (\$ Millions)

Figure 64. Russia Myelodysplastic Syndrome (MDS) Treatment Revenue Growth

2018-2023 (\$ Millions)

Figure 65. Middle East & Africa Myelodysplastic Syndrome (MDS) Treatment Sales
Market Share by Country in 2022

Figure 66. Middle East & Africa Myelodysplastic Syndrome (MDS) Treatment Revenue
Market Share by Country in 2022

Figure 67. Middle East & Africa Myelodysplastic Syndrome (MDS) Treatment Sales
Market Share by Type (2018-2023)

Figure 68. Middle East & Africa Myelodysplastic Syndrome (MDS) Treatment Sales
Market Share by Application (2018-2023)

Figure 69. Egypt Myelodysplastic Syndrome (MDS) Treatment Revenue Growth
2018-2023 (\$ Millions)

Figure 70. South Africa Myelodysplastic Syndrome (MDS) Treatment Revenue Growth
2018-2023 (\$ Millions)

Figure 71. Israel Myelodysplastic Syndrome (MDS) Treatment Revenue Growth
2018-2023 (\$ Millions)

Figure 72. Turkey Myelodysplastic Syndrome (MDS) Treatment Revenue Growth
2018-2023 (\$ Millions)

Figure 73. GCC Country Myelodysplastic Syndrome (MDS) Treatment Revenue Growth
2018-2023 (\$ Millions)

Figure 74. Manufacturing Cost Structure Analysis of Myelodysplastic Syndrome (MDS)
Treatment in 2022

Figure 75. Manufacturing Process Analysis of Myelodysplastic Syndrome (MDS)
Treatment

Figure 76. Industry Chain Structure of Myelodysplastic Syndrome (MDS) Treatment

Figure 77. Channels of Distribution

Figure 78. Global Myelodysplastic Syndrome (MDS) Treatment Sales Market Forecast
by Region (2024-2029)

Figure 79. Global Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share
Forecast by Region (2024-2029)

Figure 80. Global Myelodysplastic Syndrome (MDS) Treatment Sales Market Share
Forecast by Type (2024-2029)

Figure 81. Global Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share
Forecast by Type (2024-2029)

Figure 82. Global Myelodysplastic Syndrome (MDS) Treatment Sales Market Share
Forecast by Application (2024-2029)

Figure 83. Global Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share Forecast by Application (2024-2029)

I would like to order

Product name: Global Myelodysplastic Syndrome (MDS) Treatment Market Growth 2023-2029

Product link: <https://marketpublishers.com/r/G8D384EC1135EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G8D384EC1135EN.html>